Results 121 to 130 of about 18,748 (206)

Severe cutaneous adverse reactions associated with second-generation androgen receptor antagonists in prostate cancer patients. [PDF]

PLoS One
Liu J, Liu X, Zeng H, Tong Y, Chen Z, Dong Z.   +5 more
europepmc   +1 more source

A transition zone enriched WIF1+ basal cell subtype is associated with benign prostatic hyperplasia

The Journal of Pathology, EarlyView.
Abstract The cellular composition and disease susceptibilities of the distinct zones of the human prostate remain incompletely understood. Benign prostatic hyperplasia (BPH) is a common condition that causes widespread morbidity and is nearly exclusively localized to the transition zone (TZ).
Rulin Wang, Qizhi Zheng, Mindy K Graham, Ajay Vaghasia, Jianyong Liu, Jordan Gregg, Tracy Jones, Anuj Gupta, Nicole Castagna, Yan Zhang, Kornel Schuebel, Jennifer Meyers, Alyza Skaist, Dixie Hoyle, Jasmine Kung, Jessica Hicks, Alok Mishra, Yuhan Yang, William G Nelson, Angelo M De Marzo, Srinivasan Yegnasubramanian   +20 more
wiley   +1 more source

Scaffold transforming and in-silico design of potential androgen receptor antagonists in prostate cancer therapy. [PDF]

In Silico Pharmacol
Gupta AK, Ghode P, Jain SK.
europepmc   +1 more source

CAFs‐mediated histone lactylation reprograms cholesterol metabolism in colorectal cancer to drive CD8+ T cell immunosuppression

The Journal of Pathology, EarlyView.
Abstract The progression of colorectal cancer (CRC) is critically regulated by cancer‐associated fibroblasts (CAFs) within the tumor microenvironment (TME), yet the specific molecular mechanisms by which CAFs influence CRC remain unclear. This study reveals the mechanism by which CAFs promote CRC malignant progression and immune suppression through ...
Huachi Li, Jun Hu, Lei Huang, Zihao Wang, Haoran Tao, Feng Cao, Min Xie   +6 more
wiley   +1 more source

Differential FGFR1 copy number status displays unique tumour immune microenvironment in triple‐negative breast cancer

The Journal of Pathology, EarlyView.
Abstract Fibroblast growth factor receptor 1 (FGFR1) amplification, a significant cancer alteration with both prognostic and therapeutic relevance, lacks a standardized definition. The relationship between FGFR1 copy number (CN) variations and tumour microenvironment (TME) characteristics also remains poorly understood.
Yike Gao, Fei Yao, Junyi Pang, Tianlin Sun, Changbin Zhu, Shafei Wu, Zhiyong Liang   +6 more
wiley   +1 more source

Exploring the Reproductive Toxicity of Bisphenol S Through a Network Toxicology and Molecular Docking Analysis

Pediatric Discovery, EarlyView.
Utilizing network toxicology, molecular docking, and dynamic simulations to investigate the potential reproductive toxicity of bisphenol S (BPS). ABSTRACT The aim of this study was to investigate the potential reproductive toxicity of bisphenol S (BPS) and the related molecular mechanisms through a network toxicology approach.
Siyuan Wang, Yan Fu, Xu Huang, Qitong Guo, Xiangqin Zheng, Shengde Wu, Lianju Shen, Guanghui Wei   +7 more
wiley   +1 more source

Endocrine therapy‐induced cancer‐related fatigue in hormone‐dependent malignancies: Mechanisms, impact, and management strategies

Precision Medical Sciences, EarlyView.
Multipathway schematic of endocrine therapy–induced cancer‐related fatigue. Endocrine interventions trigger four interacting mechanisms—neuroendocrine dysregulation, systemic inflammation, energy‐metabolic failure, and psycho‐behavioral amplification—that culminate in the multidimensional CRF phenotype.
Jiajing Jiang, Jun Lu, Sen Qin, Ruzhou Chen, Qiuchen Zhang, Lvqi He, Yubei Li, Jingyao Yan   +7 more
wiley   +1 more source

Primary BPH Stromal Cell Cultures Exhibit Heightened Androgen‐Responsiveness

The Prostate, EarlyView.
ABSTRACT Background Benign prostatic hyperplasia (BPH) is the most common disease in aging males. BPH growth is androgen‐dependent, and it appears that androgens preferentially stimulate the growth of BPH as compared to normal prostate. The mechanism of preferential androgen stimulation of BPH growth is not clear.
Wei Chen, Fulu Dong, Mohammad Reza Askarpour, Laura E. Pascal, Rajiv Dhir, Uma Chandran, Bruce L. Jacobs, Donald B. DeFranco, Naoki Yoshimura, Zhou Wang   +9 more
wiley   +1 more source

Insulin‐Like Growth Factor Axis and Survival in Metastatic Hormone‐Sensitive Prostate Cancer: Post‐Hoc Analysis From the ENZAMET Phase 3 Trial

The Prostate, EarlyView.
ABSTRACT Background A higher ratio of IGF‐1:IGF binding protein 1 (IGFBP1) was associated with improved prognosis in the CHAARTED trial of docetaxel in participants with metastatic hormone‐sensitive prostate cancer (mHSPC). The ENZAMET trial demonstrated the survival benefit of adding enzalutamide to androgen deprivation therapy (ADT) in mHSPC, and ...
Michael A. Cilento, Hui‐Ming Lin, Nicole Yeung, Rachel M.N. Kim, Neil Portman, Martin R. Stockler, Andrew J. Martin, Vinod Subhash, Sonia Yip, Lisa M. Butler, Ian C. Marschner, Peter J. Meikle, Arun A. Azad, Ian D. Davis, Lisa G. Horvath, Christopher J. Sweeney   +15 more
wiley   +1 more source

Survival Outcomes by Frailty and Comorbidities in Veterans Treated With Abiraterone and Enzalutamide for Metastatic Castration‐Resistant Prostate Cancer

The Prostate, EarlyView.
ABSTRACT Background Androgen receptor pathway inhibitors (ARPIs) such as abiraterone and enzalutamide are common therapies in the management of metastatic castration‐resistant prostate cancer (mCRPC). However, the comparative effectiveness of these oral ARPIs in frail and comorbid patient populations remains uncertain.
Meghana Yellanki, Jennifer La, Danne C. Elbers, Nhan V. Do, Channing J. Paller, Nathanael R. Fillmore, Martin W. Schoen   +6 more
wiley   +1 more source